News
BCRX
8.99
+0.45%
0.04
BioCryst (BCRX) Stock After New HAE Data Presentation Is The Undervaluation Story Still Intact
Simply Wall St · 3d ago
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
Seeking Alpha · 3d ago
Weekly Report: what happened at BCRX last week (0608-0612)?
Weekly Report · 3d ago
How Investors Are Reacting To BioCryst (BCRX) Expanding Its HAE Prophylaxis Data Across Patient Groups
Simply Wall St · 4d ago
BioCryst Shareholders Approve Expanded Equity Incentive Plan
TipRanks · 6d ago
BioCryst shareholders approve amended stock incentive plan, add 7 million shares
PUBT · 6d ago
BioCryst Reports New Positive Data For ORLADEYO And Navenibart In Treating Hereditary Angioedema
NASDAQ · 6d ago
BioCryst to present new Orladeyo data at EAACI
TipRanks · 6d ago
BioCryst says post hoc ALPHA-STAR analysis shows navenibart cuts HAE attack rates across patient subgroups
PUBT · 6d ago
BIOCRYST PRESENTS NEW CLINICAL DATA AND REAL-WORLD EVIDENCE DEMONSTRATING IMPACT OF HAE PORTFOLIO AT THE 2026 EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY ANNUAL MEETING
Reuters · 6d ago
Viking Therapeutics: Drugs Are In The Pipeline, But Profitability Is Still Unproven
Seeking Alpha · 06/10 22:04
BioCryst grants 9 new hires options for 33,950 shares, RSUs for 80,650 shares under inducement plan
PUBT · 06/09 20:05
BIOCRYST REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/09 20:05
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 06/09 15:05
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Weakness
Simply Wall St · 06/08 18:19
Weekly Report: what happened at BCRX last week (0601-0605)?
Weekly Report · 06/08 09:49
Do BioCryst’s EAACI 2026 HAE Data Plans Subtly Recast the BCRX Long-Term Innovation Story?
Simply Wall St · 06/06 14:32
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances
Barchart · 06/06 02:12
These 10 mid-cap U.S. healthcare giants rank among the market's most attractively valued stocks
Seeking Alpha · 06/01 14:10
Weekly Report: what happened at BCRX last week (0525-0529)?
Weekly Report · 06/01 09:52
More
Webull provides a variety of real-time BCRX stock news. You can receive the latest news about Biocryst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.